USANA Health Sciences Financial Statements (USNA)
|
|
|
|
Report date
|
|
|
01.03.2022 |
31.12.2022 |
28.02.2023 |
31.12.2023 |
27.02.2024 |
|
05.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 186 |
998.6 |
998.6 |
921.0 |
921.0 |
|
826.2 |
|
Operating Income, bln rub |
|
|
170.2 |
107.6 |
107.6 |
93.1 |
93.1 |
|
66.9 |
|
EBITDA, bln rub |
? |
|
192.9 |
108.6 |
130.2 |
93.1 |
113.5 |
|
84.3 |
|
Net profit, bln rub |
? |
|
116.5 |
69.4 |
69.4 |
63.8 |
63.8 |
|
42.1 |
|
|
OCF, bln rub |
? |
|
121.2 |
|
103.9 |
|
70.6 |
|
37.5 |
|
CAPEX, bln rub |
? |
|
12.8 |
|
10.4 |
|
14.5 |
|
5.07 |
|
FCF, bln rub |
? |
|
108.5 |
|
93.5 |
|
56.1 |
|
32.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
0.000 |
|
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
798.4 |
697.1 |
697.1 |
651.2 |
651.2 |
|
592.7 |
|
Cost of production, bln rub |
|
|
217.9 |
193.9 |
193.9 |
176.7 |
176.7 |
|
163.0 |
|
R&D, bln rub |
|
|
11.1 |
0.000 |
11.6 |
0.000 |
11.4 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
0.057 |
0.000 |
0.192 |
0.000 |
0.262 |
|
0.200 |
|
|
Assets, bln rub |
|
|
577.7 |
596.5 |
596.5 |
632.8 |
632.8 |
|
612.5 |
|
Net Assets, bln rub |
? |
|
395.1 |
434.5 |
434.5 |
497.2 |
497.2 |
|
533.1 |
|
Debt, bln rub |
|
|
7.08 |
0.000 |
6.89 |
0.786 |
13.2 |
|
0.000 |
|
Cash, bln rub |
|
|
239.8 |
288.4 |
288.4 |
330.4 |
330.4 |
|
364.9 |
|
Net debt, bln rub |
|
|
-232.8 |
-288.4 |
-281.5 |
-329.6 |
-317.2 |
|
-364.9 |
|
|
Ordinary share price, rub |
|
|
101.2 |
53.2 |
53.2 |
53.6 |
53.6 |
|
45.1 |
|
Number of ordinary shares, mln |
|
|
20.1 |
19.2 |
19.3 |
19.3 |
19.3 |
|
19.1 |
|
|
Market cap, bln rub |
|
|
2 039 |
1 022 |
1 024 |
1 037 |
1 032 |
|
860 |
|
EV, bln rub |
? |
|
1 806 |
733 |
743 |
707 |
715 |
|
495 |
|
Book value, bln rub |
|
|
347 |
385 |
385 |
480 |
450 |
|
487 |
|
|
EPS, rub |
? |
|
5.78 |
3.61 |
3.60 |
3.30 |
3.31 |
|
2.21 |
|
FCF/share, rub |
|
|
5.38 |
0.00 |
4.86 |
0.00 |
2.92 |
|
1.70 |
|
BV/share, rub |
|
|
17.2 |
20.0 |
20.0 |
24.8 |
23.4 |
|
25.5 |
|
|
EBITDA margin, % |
? |
|
16.3% |
10.9% |
13.0% |
10.1% |
12.3% |
|
10.2% |
|
Net margin, % |
? |
|
9.82% |
6.94% |
6.94% |
6.93% |
6.93% |
|
5.09% |
|
FCF yield, % |
? |
|
5.32% |
0.00% |
9.13% |
0.00% |
5.44% |
|
3.78% |
|
ROE, % |
? |
|
29.5% |
16.0% |
16.0% |
12.8% |
12.8% |
|
7.89% |
|
ROA, % |
? |
|
20.2% |
11.6% |
11.6% |
10.1% |
10.1% |
|
6.87% |
|
|
P/E |
? |
|
17.5 |
14.7 |
14.8 |
16.3 |
16.2 |
|
20.4 |
|
P/FCF |
|
|
18.8 |
|
11.0 |
|
18.4 |
|
26.5 |
|
P/S |
? |
|
1.72 |
1.02 |
1.03 |
1.13 |
1.12 |
|
1.04 |
|
P/BV |
? |
|
5.88 |
2.66 |
2.66 |
2.16 |
2.29 |
|
1.77 |
|
EV/EBITDA |
? |
|
9.36 |
6.75 |
5.70 |
7.60 |
6.30 |
|
5.87 |
|
Debt/EBITDA |
|
|
-1.21 |
-2.66 |
-2.16 |
-3.54 |
-2.80 |
|
-4.33 |
|
|
R&D/CAPEX, % |
|
|
87.1% |
|
111.2% |
|
79.0% |
|
0 |
|
|
CAPEX/Revenue, % |
|
|
1.08% |
0.00% |
1.04% |
0.00% |
1.57% |
|
0.61% |
|
| USANA Health Sciences shareholders |
